CORBUS PHARMACEUTICALS TO REPORT RESULTS FROM PHASE 1A STUDY OF ORAL CB1 INVERSE AGONIST CRB-913 FOR THE TREATMENT FOR OBESITY ON THURSDAY, DECEMBER 11, 2025

Reuters · 1d ago

Please log in to view news